HOPKINS WASHINGTON LIFE MEDICINE LAB – Trademark Portfolio

Entity Type: 03

HOPKINS WASHINGTON LIFE MEDICINE LAB holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include TYMB, HEERBO, and IHEERBO. The owner is based in Walnut, CA.

385 S Lemon Ave, Suite E275

Walnut, CA 91789

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

HEERBO
HEERBO
Registered 2022
TYMB
TYMB
Registered 2020
IHEERBO
IHEERBO
Registered 2020

Trademark Classifications

HOPKINS WASHINGTON LIFE MEDICINE LAB's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does HOPKINS WASHINGTON LIFE MEDICINE LAB have?

HOPKINS WASHINGTON LIFE MEDICINE LAB has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does HOPKINS WASHINGTON LIFE MEDICINE LAB file in?

HOPKINS WASHINGTON LIFE MEDICINE LAB files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are HOPKINS WASHINGTON LIFE MEDICINE LAB's most well-known trademarks?

HOPKINS WASHINGTON LIFE MEDICINE LAB's registered trademark portfolio includes well-known marks such as TYMB, HEERBO, and IHEERBO. These are among 3 currently registered trademarks in the portfolio.

What is HOPKINS WASHINGTON LIFE MEDICINE LAB's trademark registration success rate?

HOPKINS WASHINGTON LIFE MEDICINE LAB has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.